Valvular & structural heart disease

Left Ventricular Function and Atrial Remodeling Shape Outcomes After Mitral-Transcatheter Edge-to-Edge Repair

ESC Heart FailPublished retrospectively analyzed

Authors' conclusion

M-TEER provides sustained clinical benefit across the LVEF spectrum, including patients with preserved LVEF. Left atrial enlargement identifies patients with worse prognosis and may represent a marker of advanced atrial disease supporting earlier intervention.

Study context

Population
Patients with symptomatic secondary mitral regurgitation (SMR) treated with mitral transcatheter edge-to-edge repair (M-TEER) between 2018 and 202287 patients with complete follow-up
Participants
93 patients
Comparison
Patients were stratified according to left ventricular ejection fraction (LVEF) and left atrial volume index
Outcome
comprehensive clinical improvement, defined as survival without heart-failure hospitalization, New York Heart Association (NYHA) class I-II, and Kansas City Cardiomyopathy Questionnaire (KCCQ) score >60
Follow-up
36 months
Methodological detailsconsecutive patients
  • Consecutive patients

Main finding

As reported in the abstract

Achieved the composite endpoint, among 87 patients with complete follow-up
48 (55%)

Further findings

OutcomeReduced LVEFPreserved LVEFLAVI <60 mL/m²LAVI ≥60 mL/m²
All-cause mortality · 36 months29.6%9.4%Not reported in the abstractNot reported in the abstractLAVI <60 mL/m², LAVI ≥60 mL/m²: not reported in the abstract
Mortality by LAVINot reported in the abstractNot reported in the abstract11.8%29.4%reduced LVEF, preserved LVEF: not reported in the abstract
  • All-cause mortality: lower in preserved LVEF; log-rank p=0.03
  • Mortality by LAVI: increased mortality with LAVI ≥60 mL/m²; log-rank p=0.04

Mortality by LAVI

In Cox regression adjusted for age and sex, LAVI remained associated with mortality risk

Original publication

Left Ventricular Function and Atrial Remodeling Shape Outcomes After Mitral-Transcatheter Edge-to-Edge Repair. ESC Heart Fail. Published 22 May 2026. doi:10.1093/eschf/xvag149

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.